Literature DB >> 26928253

Response to Comment on Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Andrew H Lipsky1, Jay N Lozier2, Adrian Wiestner3.   

Abstract

Entities:  

Keywords:  chronic lymphocytic leukemia; disorders of platelet function; laboratory hematology

Mesh：

Year:  2016        PMID： 26928253      PMCID： PMC4815745          DOI： 10.3324/haematol.2015.140558

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  6 in total

1.  Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.

Authors:  Andrew H Lipsky; Mohammed Z H Farooqui; Xin Tian; Sabrina Martyr; Ann M Cullinane; Khanh Nghiem; Clare Sun; Janet Valdez; Carsten U Niemann; Sarah E M Herman; Nakhle Saba; Susan Soto; Gerald Marti; Gulbu Uzel; Steve M Holland; Jay N Lozier; Adrian Wiestner
Journal:  Haematologica       Date:  2015-10-01       Impact factor: 9.941

2.  Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.

Authors:  S Kamel; L Horton; L Ysebaert; M Levade; K Burbury; S Tan; M Cole-Sinclair; J Reynolds; R Filshie; S Schischka; A Khot; S Sandhu; M J Keating; H Nandurkar; C S Tam
Journal:  Leukemia       Date:  2014-08-20       Impact factor: 11.528

3.  Platelet function in chronic leukemias.

Authors:  K N Naresh; P Sivasankaran; A J Veliath
Journal:  Indian J Cancer       Date:  1992-06       Impact factor: 1.224

4.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

5.  Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.

Authors:  Alexander P Bye; Amanda J Unsworth; Sakthivel Vaiyapuri; Alexander R Stainer; Michael J Fry; Jonathan M Gibbins
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-09-10       Impact factor: 8.311

6.  CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia.

Authors:  Dianne Pulte; Kim E Olson; M Johan Broekman; Naziba Islam; Harold S Ballard; Richard R Furman; Ashley E Olson; Aaron J Marcus
Journal:  J Transl Med       Date:  2007-05-04       Impact factor: 5.531
  6 in total
  3 in total

Review 1.  Managing toxicities of Bruton tyrosine kinase inhibitors.

Authors:  Andrew Lipsky; Nicole Lamanna
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

2.  Abivertinib inhibits megakaryocyte differentiation and platelet biogenesis.

Authors:  Jiansong Huang; Xin Huang; Yang Li; Xia Li; Jinghan Wang; Fenglin Li; Xiao Yan; Huanping Wang; Yungui Wang; Xiangjie Lin; Jifang Tu; Daqiang He; Wenle Ye; Min Yang; Jie Jin
Journal:  Front Med       Date:  2021-11-18       Impact factor: 9.927

Review 3.  Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.

Authors:  Maude Sestier; Christopher Hillis; Graeme Fraser; Darryl Leong
Journal:  Curr Oncol Rep       Date:  2021-08-03       Impact factor: 5.075
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.